Akeso

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to see if the combination is safe and whether it can shrink tumors. About 216 adults aged 18 to 75 will …

This phase II study tests a new drug called AK112 (a bispecific antibody that targets PD1 and VEGF) combined with standard chemotherapy in 265 people with advanced non-small cell lung cancer (stage IIIB/C or IV). The goal is to see if the combination shrinks tumors and how safe i…

This study tests two experimental drugs (AK112 and cadonilimab) plus standard chemotherapy in people with stage IV pancreatic cancer that has spread. The goal is to see if the combination is safe and can shrink tumors or slow the cancer. About 110 adults who have not had prior tr…

This phase 3 study tests whether adding the drug AK104 to standard chemotherapy (with or without bevacizumab) helps people with persistent, recurrent, or metastatic cervical cancer live longer without their disease worsening. About 445 women who have not had prior systemic therap…

This study tests a new drug called AK112, given alone or with chemotherapy, before and after surgery for people with early-stage non-small cell lung cancer that can be removed. The goal is to see if it helps shrink tumors before surgery and prevent cancer from coming back after. …

This study tests two experimental drugs (AK117 and AK112) plus chemotherapy in 120 people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if the combination shrinks tumors and is safe. Participants must have a specific type of breast c…

This study tests two experimental drugs (AK112 and AK104) given together, with or without chemotherapy, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination is safe and helps shrink tumors or s…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if these drugs can shrink tumors or slow the disease. About 254 participants will be enrolled. The study …

This phase 3 study tests whether a new drug called AK112, combined with standard chemotherapy, works better than another drug (durvalumab) plus the same chemo for people with advanced bile duct cancer that cannot be removed by surgery. About 682 participants will receive either A…

This study tests a new drug called AK112 combined with standard chemotherapy in people with a specific type of advanced lung cancer (non-squamous non-small cell) that has a mutation in the EGFR gene and has stopped responding to initial targeted therapy. About 322 participants wi…

This study tests two experimental drugs (AK112 and AK117) given together to people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink or control the tumors. About 154 adults aged 18 to 75 are taking…

This study tests two experimental drugs, AK119 and AK112, alone or with chemotherapy, in 170 adults with a specific type of colorectal cancer (pMMR/MSS) that often doesn't respond well to standard treatments. The goal is to see if these combinations can shrink tumors or slow the …

This phase 3 trial tests whether a new drug called AK112 works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 398 participants with stage IIIB/C or IV lung cancer will receive eith…

This study checks whether AK112, a drug made at a new factory, behaves the same in the body as the original version. It involves 108 healthy men aged 18 to 45. The goal is to compare drug levels and safety, not to treat any disease.